TLDR
- Blackstone plans to establish a publicly listed investment vehicle dedicated to acquiring AI data center assets, aiming to raise capital in the tens of billions
- Initial fundraising efforts will concentrate on sovereign wealth funds and large institutional capital sources
- Alongside Brookfield, Blackstone has placed bids exceeding €8 billion to acquire Volkswagen’s heavy-duty diesel engine division, Everllence SE
- Blackstone Life Sciences has entered into a collaborative funding arrangement with Johnson & Johnson for the development of bleximenib, an AML cancer treatment
- On February 23, RBC Capital began coverage of the stock with an Outperform designation and established a $179 price objective
The private equity giant is rolling out a fresh publicly listed acquisition platform designed to purchase AI data center properties. The initiative aims to provide everyday investors with exposure to AI infrastructure assets — a sector Blackstone is positioning itself to lead.
Initially, the company is focusing on attracting capital from sovereign wealth entities and major institutional backers. The longer-term vision involves scaling up to attract tens of billions from a more diverse investor population.
It represents a bold strategic bet. However, skeptics question whether the market timing is optimal.
Certain market participants have expressed worries that massive AI training complexes constructed in remote locations might lose relevance as the underlying technology continues to advance. Blackstone appears ready to address these concerns directly.
This initiative is part of a larger effort to expand beyond the firm’s traditional client segments of pension funds and university endowments. Retail market participants are now a key strategic focus.
Volkswagen Unit Bid
On the mergers and acquisitions front, Blackstone and Brookfield Asset Management (NYSE: BAM) have each put forward proposals valued at no less than €8 billion ($9.4 billion) to secure a controlling interest in Volkswagen’s Everllence SE division.
Everllence specializes in manufacturing marine propulsion systems and industrial turbines for power generation facilities. Volkswagen has been actively pursuing a sale of this asset as part of a broader corporate restructuring aimed at enhancing operational efficiency and financial returns.
Additional contenders in the competitive bidding process include Advent International, Bain Capital, EQT AB, and CVC Capital Partners — all of which have progressed to subsequent stages of evaluation.
A finalized transaction remains uncertain. Sources cited by Bloomberg indicated that negotiations are continuing.
Biotech and Analyst Coverage
On February 23, Blackstone Life Sciences revealed a co-investment partnership with Johnson & Johnson to support the clinical progression of bleximenib, an experimental oral therapy designed to treat acute myeloid leukemia.
AML represents the most prevalent form of acute leukemia diagnosed in adult populations and carries the poorest survival outcomes among all leukemia classifications. Company executives characterized it as an exceptionally challenging disease to manage therapeutically.
This marks the inaugural co-funding collaboration between BXLS and Johnson & Johnson, representing a significant development for Blackstone’s life sciences division.
On the same date, RBC Capital launched research coverage on Blackstone with an Outperform recommendation and established a $179 price objective.
RBC communicated to clients that Blackstone possesses a “first-mover advantage” as the pioneering alternatives manager to establish a dedicated private wealth distribution team. The financial institution views the company as positioned to capitalize on expanding retail investor participation and an improving commercial real estate environment.
Blackstone conducts business across four primary divisions: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions.
BX stock declined 3.88% on February 27, coinciding with the public disclosure of both the AI data center initiative and Volkswagen bidding developments.
